ReviewClinical kidney journal2026
Executive summary of the European consensus report on the diagnosis and treatment of monoclonal gammopathy of renal significance.
Review in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We introduce the European Union consensus report on the diagnosis and treatment of monoclonal gammopathy of renal significance (MGRS), a generic term to describe kidney disorders caused by a non-malignant monoclonal immunoglobulin clone. There are many subtypes of MGRS, with AL-amyloidosis being most prevalent. The consensus report aims at providing guidance to clinicians, pathologists and laboratory specialists who take care of patients with a (suspected) diagnosis of MGRS. This executive summary provides a condensed overview of the most important aspects of the diagnosis and management of patients with MGRS. Consultation of expert centers is strongly advised. Although most patients will benefit from hematological, clone-directed therapy, treatment decisions must be individualized, in view of the heterogeneity of patients between and within the MGRS subtypes. The final chapter discusses kidney transplantation in patients with MGRS. The working group acknowledges that most advice is based on low-quality evidence. The full report provides the rationale and a detailed discussion of the available literature. This executive summary is an introduction, and not a substitute for the full consensus report.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.